Drugs that contain Futibatinib

1. List of Lytgobi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9108973 TAIHO ONCOLOGY 3,5-disubstituted alkynylbenzene compound and salt thereof
Feb, 2033

(9 years from now)

US10434103 TAIHO ONCOLOGY Crystal of 3,5-disubstituted benzene alkynyl compound
Mar, 2036

(12 years from now)

Do you want to check out LYTGOBI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 30, 2027
Orphan Drug Exclusivity (ODE) Sep 30, 2029

NCE-1 date: 2026-09-30

Market Authorisation Date: 30 September, 2022

Treatment: Method of treating intrahepatic cholangiocarcinoma

Dosage: TABLET;ORAL

More Information on Dosage

LYTGOBI family patents

7

Japan

3

China

2

Spain

2

Hong Kong

2

Denmark

2

United States

2

Poland

2

Russia

2

Brazil

2

Canada

2

Singapore

2

Korea, Republic of

2

Portugal

2

Mexico

2

Australia

2

European Union

1

Philippines

1

Malaysia

1

Taiwan

1

Hungary

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in